Please login to the form below

Not currently logged in
Email:
Password:

Dificid

This page shows the latest Dificid news and features for those working in and with pharma, biotech and healthcare.

After delay, Merck gets US approval for serious infection drug

After delay, Merck gets US approval for serious infection drug

GlobalData says Merck will lead the market thanks to Dificid/Dificlir (fidaxomicin), which it predicts will be the biggest-selling antibiotic for these infections, while Zinplava could see competition in the

Latest news

  • Optimer fires Michael Chang as chair

    45m. The company has been buoyed by the US launch of diarrhoea drug Dificid, which is sold as Dificlir in Europe, the Middle East and Commonwealth of Independent States by Astellas.

  • EC approves first-in-class antibiotic Dificlir

    Fidaxomicin was approved in the US earlier this year where it is sold as Dificid.

  • Optimer antibiotic approved

    difficile-associated diarrhoea.". In clinical trials, Dificid worked as well as ViroPharma's Vancocin (vancomycin) in curing CDAD and was better than vancomycin at preventing recurrence of infection. ... Dificid, which is Optimer's first approved product,

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Pharma deals during December 2014 Pharma deals during December 2014

    The Optimer acquisition brought to Cubist an approved antibacterial drug for the treatment of Clostridium difficile-associated diarrhoea (CDAD) called DIFICID (fidaxomicin).

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    815. Optimer Pharmaceuticals / Cubist Pharmaceuticals. Acquisition. Antibiotic pipeline based on Dificid (fidaxomicin) for C.difficile (approved).

  • Pharma deals during July 2013 Pharma deals during July 2013

    Cubist had already developed a relationship with Optimer through their 2011 co-promotion agreement for Dificid (fidaxomicin), for the treatment of Clostridium difficile-associated diarrhoea (CDAD) in adults 18 years of ... Dificid was launched in the US

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics